Researchers here described how they were able to safely and ethically enroll adolescents in a landmark trial of a drug that ...

The health clinic where Alice Okwirry collects her HIV medication in Kenya's capital Nairobi has been rationing supplies of ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

During the opening day of the Conference on Retroviruses and Opportunistic Infections, Rebecca Denison, a decades-long HIV ...

ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

SAN FRANCISCO -- At least 400 researchers, physicians, activists, and other concerned citizens gathered here Monday night to ...

In the general population, frailty is an aging-related risk factor for poor outcomes; individuals experiencing frailty face ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Adults living with HIV in Malawi are more than twice as likely to also have dementia compared to those without HIV, according ...

Katrina Ortblad, ScD, MPH, Fred Hutch Cancer Center, collaborates with researchers from the Kenya Medical Research Institute ...